Meta-analysis and review on the effect of bevacizumab in diabetic macular edema

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 249, Issue 1, 2011, Pages 15-27

  Goyal, Sunali ^a   Lavalley, Michael ^b   Subramanian, Manju L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Angiogenesis; Anti VEGF therapy; Avastin; Bevacizumab; Diabetic macular edema

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ANEMIA; ARTICLE; CENTRAL SUBFIELD MACULAR THICKNESS; COCHRANE LIBRARY; CONGESTIVE HEART FAILURE; DIABETIC MACULAR EDEMA; DRUG DOSE COMPARISON; DRUG EFFICACY; ENDOPHTHALMITIS; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; KIDNEY DYSFUNCTION; LASER COAGULATION; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETINA DETACHMENT; SHORT COURSE THERAPY; SIDE EFFECT; SYNCOPE; SYSTEMATIC REVIEW; TREATMENT DURATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULA LUTEA; MACULAR EDEMA; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79951725232     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1452-4     Document Type: Article

References (51)

1. R Klein BE Klein SE Moss 1984 Visual impairment in diabetes Ophthalmology 91 1 9 1:STN:280:DyaL2c7mvFSisw%3D%3D 6709312 (Pubitemid 14184710)
2. SE Moss R Klein BE Klein 1994 Ten-year incidence of visual loss in a diabetic population Ophthalmology 101 1061 1070 1:STN:280:DyaK2c3nslGitA%3D%3D 8008348 (Pubitemid 24183163)
3. GH Bresnick 1986 Diabetic macular edema. A review Ophthalmology 93 989 997 1:STN:280:DyaL2s%2FhsFOntQ%3D%3D 3531959 (Pubitemid 16046114)
4. R Klein BE Klein SE Moss MD Davis DL DeMets 1984 The Wisconsin epidemiologic study of diabetic retinopathy: III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years Arch Ophthalmol 102 527 532 1:STN:280:DyaL2c7ltlCktg%3D%3D 6367725 (Pubitemid 14127839)
5. R Klein BE Klein SE Moss MD Davis DL DeMets 1984 The Wisconsin epidemiologic study of diabetic retinopathy: IV. Diabetic macular edema Ophthalmology 91 1464 1474 1:STN:280:DyaL2M7htF2rsg%3D%3D 6521986 (Pubitemid 15197017)
6. RJ Antcliff J Marshall 1999 The pathogenesis of edema in diabetic maculopathy SemiOphthalmol 14 223 32 1:STN:280:DC%2BD3c3isVSitw%3D%3D (Pubitemid 30061165)
7. PR Aroca M Salvat J Fernández I Méndez 2004 Risk factors for diffuse and focal macular edema J Diabetes Complications 18 211 215 10.1016/S1056-8727(03)00038-2 15207838 (Pubitemid 38781135)
8. Early Treatment Diabetic Retinopathy Study Research Group 1985 Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report no 1 Arch Ophthalmol 103 1796 1806
9. FP Nasrallah AE Jalkh F Van Coppenolle M Kado CL Trempe JW McMeel CL Schepens 1988 The role of the vitreous in diabetic macular edema Ophthalmol 95 1335 1339 1:STN:280:DyaL1M7ksVCjug%3D%3D
10. JB Jonas I Kreissig A Sofker RF Degenring 2003 Intravitreal injection of triamcinolone for diffuse diabetic macular edema Arch Ophthalmol 121 57 61 1:CAS:528:DC%2BD3sXps1KqsQ%3D%3D 10.1001/archopht.121.5.729 12523885 (Pubitemid 36554480)
11. A Loewenstein M Goldstein 2006 Intravitreal triamcinolone acetonide for diabetic macula edema Isr Med Assoc J 8 426 427 16833175 (Pubitemid 43986059)
12. MB Grant A Afzal P Spoerri H Pan LC Shaw RN Mames 2004 The role of growth factors in the pathogenesis of diabetic retinopathy Expert Opin Investig Drugs 13 1275 1293 1:CAS:528:DC%2BD2cXotVOnuro%3D 10.1517/13543784.13.10.1275 15461557 (Pubitemid 39359658)
13. LP Aiello RL Avery PG Arrigg BA Keyt HD Jampel ST Shah LR Pasquale H Thieme MA Iwamoto JE Park 1994 Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1480 1487 1:STN:280:DyaK2M%2FlvFamsA%3D%3D 10.1056/NEJM199412013312203 7526212 (Pubitemid 24356306)
14. H Funatsu H Yamashita T Ikeda Y Nakanishi S Kitano S Hori 2002 Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders Am J Ophthalmol 133 537 543 1:CAS:528:DC%2BD38XisV2rtLg%3D 10.1016/S0002-9394(02)01323-5 11931788 (Pubitemid 34258063)
15. ET Cunningham Jr AP Adamis M Altaweel LP Aiello NM Bressler DJ D'Amico M Goldbaum B Katz M Patel SD Schwartz Macugen Diabetic Retinopathy Study Group 2005 A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmol 112 1747 1757 10.1016/j.ophtha.2005.06.007 (Pubitemid 41400011)
16. DW Chun JS Heier TM Topping JS Duker JM Bankert 2006 A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema Ophthalmol 113 1706 1712 10.1016/j.ophtha.2006.04.033 (Pubitemid 44442451)
17. J Whisenant E Bergsland 2005 Anti-angiogenic strategies in gastrointestinal malignancies Curr Treat Options Oncol 6 411 421 10.1007/s11864-005-0044-8 16107244 (Pubitemid 41684221)
18. PK Kaiser 2006 Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases Am J Ophthalmol 142 660 668 1:CAS:528:DC%2BD28XhtVWqtbnF 10.1016/j.ajo.2006.05.061 17011860 (Pubitemid 44442083)
19. SS Lynch CM Cheng 2007 Bevacizumab for neovascular ocular diseases Ann Pharmacother 41 614 625 1:CAS:528:DC%2BD2sXltlOnsrs%3D 10.1345/aph.1H316 17355998 (Pubitemid 46625484)
20. AE Fung PJ Rosenfeld E Reichel 2006 The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide Br J Ophthalmol 90 1344 1349 1:STN:280:DC%2BD28nit1Sltw%3D%3D 10.1136/bjo.2006. 099598 16854824 (Pubitemid 44702055)
21. M Soheilian A Ramezani B Bijanzadeh M Yaseri H Ahmadieh MH Dehghan M Azarmina S Moradian H Tabatabaei GA Peyman 2007 Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema Retina 27 1187 1195 10.1097/IAE.0b013e31815ec261 18046223 (Pubitemid 350211523)
22. Diabetic Retinopathy Clinical Research Network 2007 A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema Ophthalmology 114 1860 1867 10.1016/j.ophtha.2007.05.062 (Pubitemid 47483934)
23. H Ahmadieh A Ramezani N Shoeibi B Bijanzadeh A Tabatabaei M Azarmina M Soheilian G Keshavarzi MR Mohebbi 2008 Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial Graefes Arch Clin Exp Ophthalmol 246 483 489 1:CAS:528:DC%2BD1cXjsF2gsbo%3D 10.1007/s00417-007-0688-0 17917738 (Pubitemid 351447960)
24. H Faghihi R Roohipoor SF Mohammadi K Hojat-Jalali A Mirshahi A Lashay N Piri Sh Faghihi 2008 Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema Eur J Ophthalmol 18 941 948 1:STN:280:DC%2BD1cjitFagtg%3D%3D 18988166
25. M Soheilian A Ramezani A Obudi B Bijanzadeh M Salehipour M Yaseri H Ahmadieh MH Dehghan M Azarmina S Moradian GA Peyman 2009 Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema Ophthalmology 116 1142 1150 10.1016/j.ophtha.2009.01.011 19376585
26. L Paccola RA Costa MS Folgosa JC Barbosa IU Scott R Jorge 2008 Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study) Br J Ophthalmol 92 76 80 1:STN:280:DC%2BD2sjmtFWisw%3D%3D 10.1136/bjo.2007.129122 17965109
27. DS Lam TY Lai VY Lee CK Chan DT Liu S Mohamed CL Li 2009 Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial Retina 29 292 299 10.1097/IAE. 0b013e31819a2d61 19287286
28. C Haritoglou D Kook A Neubauer A Wolf S Priglinger R Strauss A Gandorfer M Ulbig A Kampik 2006 Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema Retina 26 999 1005 10.1097/01.iae.0000247165. 38655.bf 17151486 (Pubitemid 44973218)
29. JF Arevalo J Fromow-Guerra H Quiroz-Mercado Pan-American Collaborative Retina Study Group 2007 Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up Ophthalmology 114 743 750 10.1016/j.ophtha.2006.12.028 17398322 (Pubitemid 46483714)
30. A Yanyali B Aytug F Horozoglu AF Nohutcu 2007 Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes Am J Ophthalmol 144 124 126 1:CAS:528:DC%2BD2sXntF2kur4%3D 10.1016/j.ajo.2007.02.048 17601433 (Pubitemid 46963178)
31. A Kumar S Sinha 2007 Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population Indian J Ophthalmol 55 451 455 10.4103/0301-4738.36481 17951903
32. K Ornek N Ornek 2008 Intravitreal bevacizumab treatment for refractory diabetic macular edema J Ocul Pharmacol Ther 24 403 407 1:CAS:528: DC%2BD1cXptFCgs7k%3D 10.1089/jop.2007.0128 18627339
33. D Kook A Wolf T Kreutzer A Neubauer R Strauss M Ulbig A Kampik C Haritoglou 2008 Long-term effect of intravitreal bevacizumab (avastin) inpatients with chronic diffuse diabetic macular edema Retina 28 1053 1060 10.1097/IAE.0b013e318176de48 18779710
34. MI Roh SH Byeon OW Kwon 2008 Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema Retina 28 1314 1318 10.1097/IAE.0b013e3181853d2a 18728621
35. X Fang H Sakaguchi F Gomi Y Oshima M Sawa M Tsujikawa Y Ikuno M Kamei S Kusaka Y Tano 2008 Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema Acta Ophthalmol 86 800 805 10.1111/j.1755-3768.2008.01254.x 18547274
36. W Soliman M Vinten B Sander KA Soliman S Yehya MS Rahman M Larsen 2008 Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema Acta Ophthalmol 86 365 371 10.1111/j.1600-0420.2007.01057.x 18028237
37. JW Seo IW Park 2009 Intravitreal bevacizumab for treatment of diabetic macular edema Korean J Ophthalmol 23 17 22 1:CAS:528:DC%2BC3cXptVajt7g%3D 10.3341/kjo.2009.23.1.17 19337474
38. R Velez-Montoya J Fromow-Guerra O Burgos MB Landers 3rd V Morales-Catón H Quiroz-Mercado 2009 The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study Retina 29 20 26 10.1097/IAE.0b013e318186c64e 18784623
39. JF Arevalo JG Sanchez J Fromow-Guerra Pan-American Collaborative Retina Study Group 2009 Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up Graefes Arch Clin Exp Ophthalmol 247 735 43 1:CAS:528:DC%2BD1MXlt1Kju78%3D 10.1007/s00417-008-1034-x 19189118
40. M Bonini-Filho RA Costa D Calucci R Jorge LA Melo Jr IU Scott 2009 Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study Am J Ophthalmol 147 1022 1030 1:CAS:528:DC%2BD1MXmtlOlt78%3D 10.1016/j.ajo.2009.01.009 19327746
41. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for Meta-Analysis in Medical Research. John Wiley & Sons, New York, pp 31-33
42. AP Verhagen HC de Vet RA de Bie AG Kessels M Boers LM Bouter PG Knipschild 1998 The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus J Clin Epidemiol 51 1235 1241 1:STN:280:DyaK1M7osVKiuw%3D%3D 10.1016/S0895-4356(98)00131-0 10086815 (Pubitemid 29009523)
43. JPT Higgins SG Thompson JJ Deeks DG Altman 2003 Measuring inconsistency in meta-analysis BMJ 327 557 560 10.1136/bmj.327.7414.557 12958120
44. S-L Normand 1999 Tutorial in biostatistics: meta-analysis: formulating, evaluating, combining and reporting Stat Med 18 321 359 1:STN:280: DyaK1M7mvFyrsQ%3D%3D 10.1002/(SICI)1097-0258(19990215)18:3<321::AID- SIM28>3.0.CO;2-P 10070677 (Pubitemid 29057459)
45. SJ Bakri MR Snyder JM Reid JS Pulido RJ Singh 2007 Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology 114 855 859 10.1016/j.ophtha.2007.01.017 17467524 (Pubitemid 46635858)
46. RM Dafer M Schneck TR Friberg WM Jay 2007 Intravitreal ranibizumab and bevacizumab: a review of risk Semin Ophthalmol 22 201 204 10.1080/ 08820530701543024 17763246 (Pubitemid 47346972)
47. RB Bhisitkul 2006 Vascular endothelial growth factor biology: clinical implications for ocular treatments Br J Ophthalmol 90 1542 1547 1:STN:280:DC%2BD28nnsVynsg%3D%3D 10.1136/bjo.2006.098426 17114590 (Pubitemid 44862578)
48. MC Gillies 2006 What we don't know about avastin might hurt us Arch Ophthalmol 124 1478 1479 10.1001/archopht.124.10.1478 17030717 (Pubitemid 44537150)
49. FC Schlichtenbrede W Mittmann F Rensch F Vom Hagen JB Jonas T Euler 2009 Toxicity assessment of intravitreal triamcinolone and bevacizumab in an retinal explant mouse model using two-photon microscopy Invest Ophthalmol Vis Sci 50 5880 5887 10.1167/iovs.08-3078 19578025
50. L Wu MA Martínez-Castellanos H Quiroz-Mercado JF Arevalo MH Berrocal ME Farah M Maia JA Roca FJ Rodriguez Pan American Collaborative Retina Group (PACORES) 2008 Twelve-month safety of intravitreal injections of bevacizumab(Avastin): results of the Pan-American Collaborative RetinaStudy Group (PACORES) Graefes Arch Clin Exp Ophthalmol 246 81 87 1:CAS:528: DC%2BD2sXhtlaqsbbP 10.1007/s00417-007-0660-z 17674014 (Pubitemid 350167096)
51. M O'Doherty I Dooley M Hickey-Dwyer 2008 Interventions for diabetic macular oedema: a systemic review of literature Br J Ophthalmol 92 1581 1590 10.1136/bjo.2008.144550 18952646